Nkarta Q3 2022 net loss $28.3M; cash $395.1M; NKX019 dose expansion opened

Nkarta, Inc.

2022-Q3 EPS reported -$1.94

Net loss of $28.3M ($0.58 per share); R&D expense $23.4M, G&A $6.8M.
Cash, equivalents, and investments $395.1M; expected to fund operations into 2025.
NKX019 dose expansion cohorts opened; clinical update expected by year-end 2022.
NKX101 data for r/r AML timeline pushed to first half of 2023.
SITC presentations on NKX019+CD20 mAb combination and scalable NK cell manufacturing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Nkarta, Inc. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 9, 2022, Nkarta, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2022.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Nkarta, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-023827

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.